CRISPR, Vertex say FDA puts brakes on upcoming gene editing trial

Cambridge startup CRISPR Therapeutics and Boston-based Vertex Pharmaceuticals said on Wednesday that the FDA has put on hold a highly anticipated upcoming trial of their experimental gene editing drug for sickle cell disease. CRISPR (Nasdaq: CRISPR) and Vertex (Nasdaq: VRTX) announced after markets closed on Wednesday that the FDA had halted the upcoming trial, which hasn't started yet. The companies sought approval in April to begin the early-stage study in humans; it would be one of the first…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news